A single injection has shown a 70% improvement in pain associated with OA for two years (Figure 1).
Patients that crossed-over from Hyaluronic Acid (HA) to nSTRIDE APS experienced a significant pain reduction at one-year compared to patients that switched from nSTRIDE APS to HA.
A clinical study showed a positive correlation between APS/WBC concentration and early pain relief, with improved WOMAC pain scores at six months post-injection and nSTRIDE APS demonstrated significant pain improvement compared to saline at one-year using a novel responder criteria.
Effusions (≥5 mL) significantly decreased nine months after one injection.
64% of patients avoided additional knee treatments five years post-injection.
Significant improvements in pain, function, stiffness, and total scores at one-year.
Patients reported improvement in knee osteoarthritis symptoms one year after injection'
nSTRIDE APS can reduce cartilage degeneration by introducing anti-inflammatory cytokines (IL-1ra, sIL-1RII, sTNF-RI, sTNF-RII) that:
Block cartilage-degrading enzyme MMP-13.
Reduce cartilage breakdown debris in the joint.
Decrease pro-inflammatory cytokines in the synovium.' ' '
High levels of anti-inflammatory cytokines and anabolic growth factors help halt OA progression and restore balance. '
Demonstrated pain relief from osteoarthritis of the knee for up to two years with a single injection.
